Loading
Stage Iv Lung Cancer AJCC V8 / Computed Tomography / Atezolizumab · Phase 1/2 Trial
ClinicalTrials.gov · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1/2 trial registration for a novel combination of iadademstat (an LSD1 inhibitor) with checkpoint inhibitors (atezolizumab or durvalumab) in treatment-refractory extensive-stage small cell lung cancer. No results are posted in this registry record; the study is currently recruiting.
Phase 1/2, Interventional, Randomized, Sequential, Open label, Treatment purpose. Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8; age from 18 Years. Intervention: Phase I (iadademstat, atezolizumab, durvalumab); Phase II, Arm I (iadademstat, atezolizumab, durvalumab). Compared with: Phase II Arm II (atezolizumab, durvalumab) — Active Comparator. n = 45. 43 sites: United States.
This is a Phase 1/2 trial registration for a novel combination of iadademstat (an LSD1 inhibitor) with checkpoint inhibitors (atezolizumab or durvalumab) in treatment-refractory extensive-stage small cell lung cancer. No results are posted in this registry record; the study is currently recruiting.
This is a registry record only; no efficacy, safety, or outcome data are reported.
This trial is exploratory and addresses an unmet need in treatment-refractory small cell lung cancer. Clinicians should await results before considering this combination outside a trial setting.
This is a Phase 1/2 trial registration with no posted results; it describes a planned early-phase study of a novel combination in a difficult-to-treat cancer.
As stated by the source record.
Quoted from the source exactly as published.
This trial is exploratory and addresses an unmet need in treatment-refractory small cell lung cancer. Clinicians should await results before considering this combination outside a trial setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06287775). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 45 participants (ESTIMATED). Conditions: Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8. Interventions: BIOLOGICAL: Atezolizumab; PROCEDURE: Biopsy Procedure; PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; BIOLOGICAL: Durvalumab; PROCEDURE: Echocardiography Test; DRUG: Iadademstat; PROCEDURE: Magnetic Resonance Imaging; PROCEDURE: Multigated Acquisition Scan. Primary outcome measures: Progression free survival , From start of treatment to time of progression or death, whichever occurs first, up to 2 years. Brief summary: This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spread outside of the lung in which it began or to other parts of the body (extensive stage) who initially received standard of care chemotherapy and immunotherapy. Iadademstat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab or durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding iadademstat to either atezolizumab or durvalumab may be able to stabilize cancer for longer than atezolizumab or durvalumab alone in treating patients with extensive stage small cell lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.